ClinicalTrials.gg
Active, not recruitingNCT04011150VVAMBUpdated Aug 14, 2026

Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour

A Phase 3 interventional study of Epidural infusion pump and Ropivacaine in Labor Pain and Breakthrough Pain, sponsored by KK Women's and Children's Hospital. Active, not recruiting at 1 site in Singapore. Open to female participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by KK Women's and Children's Hospital · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
Female
01

Study summary

A novel epidural delivery regimen was developed: Variable volume automated mandatory bolus (AMB) (VVAMB) will advance individualisation of labour epidural analgesia, by which a larger volume of bolus may contribute to better spread of the local anaesthetics within brief period and thereby reduces the chances of motor blockade that could reduce instrumental deliveries.

Read the detailed description

Epidural analgesia is the gold standard of pain relief for labour pain. Despite this, up to 50% of parturients continue to experience pain leading to suffering and increased caregiver workload. There is also higher risk of motor blockade found in those receiving epidural analgesia, and these factors is associated with dysfunctional labour requiring obstetric intervention (instrumental delivery). Automated mandatory bolus (AMB) of variable-frequency (VAMB) has been shown to provide better pain relief as compared with conventional patient-controlled epidural analgesia (PCEA) with basal infusion, however its long lockout time per hour is associated with unsuccessful patient bolus requests, with similar motor block to conventional regimens.

The investigators therefore proposes to develop a novel epidural delivery regimen: Variable volume AMB (VVAMB) will advance individualisation of labour epidural analgesia, by which a larger volume of bolus may contribute to better spread of the local anaesthetics within brief period and thereby reduces the chances of motor blockade that could reduce instrumental deliveries. This algorithm development including pilot and clinical trial will compare VVAMB with VAMB regimens, in reducing the incidence of motor block in term women requesting for labour epidural analgesia.

02

Conditions studied

  • Labor Pain
  • Breakthrough Pain

Keywords

  • Labor Pain
  • Breakthrough Pain
  • Infusion pump
03

In context

Labor Pain

423 studies on the registry are indexed under Labor Pain; 74 are open to participants now.

This study's enrollment of 197 is above the median of 100 across 347 interventional studies indexed under Labor Pain.

Browse Labor Pain studies →

Lead sponsor

KK Women's and Children's Hospital is the lead sponsor of 137 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy ( (ASA) physical status 1 and 2) primiparous parturient at term (≥36 weeks gestation);
  • Singleton fetus;
  • In early labor stage (cervical dilation ≤5cm);
  • Request labor epidural analgesia and able to administer combined spinal epidural analgesia (CSEA) according to protocol.

Exclusion criteria

Exclusion Criteria:

  • Non-cephalic fetal presentation;
  • Obstetric (e.g. pre-eclampsia, premature rupture of amniotic membranes for more than 48 hours, gestational diabetes on insulin, pregnancy-induced hypertension on medication) and uncontrolled medical (e.g. cardiac disease) complications;
  • Have to neuraxial blockade or have received parenteral opioids within last 2 hours;
  • Dural puncture/ suspected dural puncture at initiation of CSEA.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Variable volume Automated Mandatory Bolus (VVAMB)

    The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VVAMB programme. The programme uses higher doses with lower frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.

    Device: Epidural infusion pump · Drug: Ropivacaine · Drug: Fentanyl

  • Active comparator
    Automated mandatory bolus (AMB) of variable-frequency (VAMB)

    The anaesthetic drug and pain medication are prepared in an epidural infusion pump with the VAMB programme. The programme uses lower doses with more frequency of medication (ropivacaine and fentanyl), and a patient control button for the patient to control the additional pain relief demands depending on the requirements during labour.

    Device: Epidural infusion pump · Drug: Ropivacaine · Drug: Fentanyl

Interventions

  • DeviceEpidural infusion pump

    Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

    Also known as: Epidural delivery system

  • Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

    Also known as: Amide local anaesthetic

  • Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

    Also known as: Opioid

06

What researchers measure

Primary outcomes

  1. Incidence of motor block in each group

    The number of event of motor block throughout the labour. Previous studies have shown that epidural analgesia using high concentrations of local anaesthetics could lead to decreased motor functions, and are subsequently associated with an increased incidence of instrumented delivery and longer second stage of labour. In this study, the intensity of motor block is assessed by the patient's ability to move their lower extremities via a modified Bromage scale. In the modified version, a scoring of 0 implies no motor block (Free movement of both legs and feet), scoring of 1 implies partial block (Just able to flex knees with free movement of feet), 2 implies almost complete block (Unable to flex knees but with free movement of feet) and 3 implies a full block (Unable to move legs/ feet).

    Time frame: During labour (1 day)

Secondary outcomes

  1. Number of subjects with Instrumental delivery

    The number of subjects in each group having instrumental delivery (forceps, vacuum delivery)

    Time frame: During labour (1 day)

  2. Number of subjects with Breakthrough pain

    The number of subjects in each group having unscheduled epidural supplementation by anaesthetist due to labor pain

    Time frame: During labour (1 day)

  3. APGAR score

    The Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) score is a test given to newborns soon after birth. In the test, five are being evaluated: Appearance (skin color), Pulse (heart rate), Grimace response (reflexes), Activity (muscle tone) and Respiration (breathing rate and effort). Each is scored on a scale of 0 to 2, with 2 being the best score; a total score of ten represents the best possible condition.

    Time frame: After delivery (1 day)

  4. The incidence of postnatal depression in both groups

    Incidence of postnatal depression will be assessed via Edinburgh Postnatal Depression Scale (EPDS) score at week 8 after delivery. EPDS is a 10-item self reporting scale to evaluate the postnatal depression. Participants are asked to respond according to how they have felt in the past seven days. Each item is measured on a 4-point scale (0-3), with a total score in the range of 0 to 30. A higher total score indicates a greater degree of depressive symptoms. A score of 10 and above indicates clinically significant depressive symptoms.

    Time frame: 6-10 weeks after delivery (1 day)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jul 2022, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2019
First posted
Jul 8, 2019
StartActual
Aug 11, 2020
Primary completionActual
Jul 28, 2022
CompletionEst.
Aug 31, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04011150
Responsible party
Sng Ban Leong (Principal Investigator, KK Women's and Children's Hospital) — Principal investigator
First posted
Jul 8, 2019
Start date
Aug 11, 2020
Primary completion
Jul 28, 2022
Completion
Aug 31, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Wan Ling Leong, FANZCA
principal investigator · KK Women's and Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ropivacaine · Fentanyl

Start the discussion